Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CAO Sells $18,332.16 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREGet Free Report) CAO Theodore Alan Huizenga sold 341 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $53.76, for a total value of $18,332.16. Following the sale, the chief accounting officer now owns 41,380 shares of the company’s stock, valued at approximately $2,224,588.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE opened at $50.85 on Friday. The business has a fifty day moving average price of $47.22 and a two-hundred day moving average price of $41.46. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $31.52 and a fifty-two week high of $54.98.

Ultragenyx Pharmaceutical (NASDAQ:RAREGet Free Report) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.52) EPS for the quarter, topping analysts’ consensus estimates of ($1.65) by $0.13. The company had revenue of $127.39 million during the quarter, compared to analysts’ expectations of $119.38 million. Ultragenyx Pharmaceutical had a negative return on equity of 369.54% and a negative net margin of 139.70%. Ultragenyx Pharmaceutical’s revenue was up 23.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($2.16) EPS. As a group, research analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.37 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on RARE shares. JPMorgan Chase & Co. boosted their price target on Ultragenyx Pharmaceutical from $84.00 to $88.00 and gave the company an “overweight” rating in a research note on Tuesday, February 27th. Robert W. Baird boosted their target price on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the company an “outperform” rating in a research report on Tuesday, January 30th. Canaccord Genuity Group raised their price target on shares of Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the stock a “buy” rating in a research report on Wednesday, February 21st. Wedbush lifted their price objective on shares of Ultragenyx Pharmaceutical from $47.00 to $48.00 and gave the stock a “neutral” rating in a research note on Friday, February 16th. Finally, Wells Fargo & Company began coverage on shares of Ultragenyx Pharmaceutical in a research report on Friday, December 8th. They set an “overweight” rating and a $72.00 target price on the stock. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $91.18.

View Our Latest Report on Ultragenyx Pharmaceutical

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Sands Capital Management LLC acquired a new position in Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $123,335,000. RTW Investments LP increased its holdings in shares of Ultragenyx Pharmaceutical by 27.4% during the fourth quarter. RTW Investments LP now owns 6,887,086 shares of the biopharmaceutical company’s stock worth $329,340,000 after buying an additional 1,481,997 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Ultragenyx Pharmaceutical by 19.9% in the 4th quarter. Vanguard Group Inc. now owns 8,673,432 shares of the biopharmaceutical company’s stock valued at $414,764,000 after acquiring an additional 1,440,264 shares during the last quarter. Norges Bank acquired a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at $36,846,000. Finally, BlackRock Inc. grew its position in Ultragenyx Pharmaceutical by 12.4% during the 1st quarter. BlackRock Inc. now owns 4,873,356 shares of the biopharmaceutical company’s stock worth $195,422,000 after acquiring an additional 536,513 shares during the last quarter. Institutional investors own 96.37% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

(Get Free Report)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

See Also

Insider Buying and Selling by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.